Author:
Oishi Mayumi,Shinjo Keiko,Takanari Keisuke,Muraoka Ayako,Suzuki Miho M.,Kanbe Miki,Higuchi Shinichi,Ebisawa Katsumi,Hashikawa Kazunobu,Kamei Yuzuru,Kondo Yutaka
Abstract
AbstractKeloids are characterized by abnormal wound healing with excessive accumulation of extracellular matrix. Myofibroblasts are the primary contributor to extracellular matrix secretion, playing an essential role in the wound healing process. However, the differences between myofibroblasts involved in keloid formation and normal wound healing remain unclear. To identify the specific characteristics of keloid myofibroblasts, we initially assessed the expression levels of well-established myofibroblast markers, α-smooth muscle actin (α-SMA) and transgelin (TAGLN), in scar and keloid tissues (n = 63 and 51, respectively). Although myofibroblasts were present in significant quantities in keloids and immature scars, they were absent in mature scars. Next, we conducted RNA sequencing using myofibroblast-rich areas from keloids and immature scars to investigate the difference in RNA expression profiles among myofibroblasts. Among significantly upregulated 112 genes, KN motif and ankyrin repeat domains 4 (KANK4) was identified as a specifically upregulated gene in keloids. Immunohistochemical analysis showed that KANK4 protein was expressed in myofibroblasts in keloid tissues; however, it was not expressed in any myofibroblasts in immature scar tissues. Overexpression of KANK4 enhanced cell mobility in keloid myofibroblasts. Our results suggest that the KANK4-mediated increase in myofibroblast mobility contributes to keloid pathogenesis.
Funder
The Japan Society for the Promotion of Science KAKENHI
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Abergel, R. P. et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J. Investig. Dermatol. 84, 384–390 (1985).
2. Alibert, J.-L.-M. Descriptions des maladies de la peau observées a l'Hôpital Saint-Louis, et exposition des meilleures méthodes suivies pour leur traitement. Paris: Barrois l’ainé. vol. 2 (1806).
3. Karppinen, S. M., Heljasvaara, R., Gullberg, D., Tasanen, K. & Pihlajaniemi, T. Toward understanding scarless skin wound healing and pathological scarring. F1000Res 8, 787 (2019).
4. Macarak, E. J., Wermuth, P. J., Rosenbloom, J. & Uitto, J. Keloid disorder: Fibroblast differentiation and gene expression profile in fibrotic skin diseases. Exp. Dermatol. 30, 132–145 (2021).
5. Walsh, L. A. et al. Keloid treatments: An evidence-based systematic review of recent advances. Syst. Rev. 12, 42 (2023).